NCT03564197

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

18F-PD-L1 PET/CT to Predict Response to Nivolumab in Patients With NSCLC

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: The Netherlands Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multicenter single arm biomarker exploration and validation study. Eighty patients with NSCLC that are eligible for first line chemo-immunotherapy, first line nivolumab/ipilimumab or 2nd line and beyond PD-(L)1 immunotherapy monotherapy according to EMA label and national guidelines will be enrolled in this trial. All subjects will undergo a whole body 18F-PD-L1 PET/CT scan before start of nivolumab containing treatment. Patients will continue treatment until disease progression, withdrawal of patient consent or unacceptable toxicity.

Detailed description

18F-PD-L1 PET/CT scan to predict durable reponse to nivolumab containing treatment in patients with NSCLC

Conditions

• NSCLC Stage IV

Interventions

Type	Name	Description
OTHER	18F-PD-L1	18F-PD-L1 PET/CT scan

Timeline

• Start date: 2018-10-25
• Primary completion: 2025-01-30
• Completion: 2026-01-30
• First posted: 2018-06-20
• Last updated: 2026-02-27

Locations

8 sites across 1 country: Netherlands